top of page
enzyme.png
  • LinkedIn
  • Twitter
  • Youtube

“One stop shop”
for wound care solutions

Our approach combines, cell therapies, enzyme technology and medical devices

BoldBrain

Challenge 2022

WINNER

Healiva SA_investordeckII.011.png

Offering end-to-end  chronic wound care solutions, which are personalized and affordable

Healiva is a patient-centric Biotech commercializing a portfolio of innovative, personalized and affordable therapies for chronic and acute wounds and targeting key pain points in the patient care pathway. 

Epidex®
Epidermal cell graft

Personalized treatment  for the most severe chronic wounds

AQUAtyrp
Healiva 003
Enzymatic debriding agent 

Painless, easy-to-use and more effective for wound cleaning and preparation.

Healiva 002
Allogenic cell spray

Growth factor stimulation with ability to scale to large number of patients

Healiva 004
Blood Patch

Autologous patch prepared at Point of Care by healthcare professional.

No satisfactory therapy for hard-to-heal wounds currently exists…

There are 156m patients are estimated in the world to suffer from chronic wounds :


- 2-3% of the elderly have painful    Venous/Arterial Leg Ulcers 
- 25% of diabetics have disabling diabetic foot ulcers 

- 60% of chronic wounds remain unhealed 

… and the treatment is very costly  

- Repeated surgical procedures 
- Requirement of medical expertise
- Frequency of dressing changes 
- Lengthy hospital stays
This is inefficient and is a financial burden on patients and society

Product Pipeline

2024

Cell Therapy -

Epidex / Healiva 001 

2025

Wound Debriber -

AQUAtyrp / Healiva 003 

2026

Medical Device –

Blood patch / Healiva 004 

2027

Cell Therapy –

Allogenic cell therapy / Healiva 002

Member of :

ewma_white_logo.jpg
swiss_startup_white.jpg
farma_logo_white.jpg
swiss_health_white.jpg
usi_white.jpg
bottom of page